Wunderlich Securities Downgrades Synovus Financial (SNV) to Sell; Disappointing Qtr
More News related to SNV
- Synovus Reiterates Capital Adequacy Under SCAP Stress Testing
- Notable 52-Week NYSE New Highs and Lows 11/19: CAH, DCI, RX, KG, MRK, TSL Highs; SNV, WNR Low
- Synovus Reaffirms Capital Position
- Notable Analyst Rating Changes 11/11: SMI, TOL, SFD, MCHP Upgraded; PCLN, SNV, RHIE, ADBE, SIGM, HUM Downgraded
- Morgan Keegan Downgrades Synovus Financial (SNV) to Market Perform
More News related to Downgrades
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
Wunderlich Securities downgrades Synovus Financial (NYSE: SNV) from Hold to Sell. Price target $1.50.
Wunderlich analyst says, "We are downgrading Synovus to Sell with a price target of $1.50 following yet another quarterly disappointment. The Q309 shortfall versus our estimate was largely due to significantly higher credit costs than we expected. With the disturbing credit trends that were evident in Q309, we are doubtful that the company can return to profitability anytime soon; thus, continued losses will likely erode TBV/share significantly over the next 12 to 18 months. Despite a recently completed $600 million equity offering, our model suggests that additional capital could be needed if Synovus is to survive this credit cycle, which would likely erase any remaining value for existing shareholders."
To see more analyst ratings on SNV Click Here.
Related Categories
DowngradesStocks Mentioned
+0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
